Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study

Abstract

Patients with rheumatic diseases (RD) are considered to be a high-risk population for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The effectiveness of inactivated COVID-19 vaccinations (ICVs) was described as more effective than 95%. Despite this, no data on the immunogenicity and safety of the ICV in Han race stable RD patients in China. In this study, we sought to assess the safety and immunogenicity of the ICVs in RD patients in South China. A total of 80 adult stable RD patients were recruited. Following 14–35 days of immunization, cheiluminescence immunoassays (CLIA) were utilized to detect antibodies titers. An investigation into the relative parameters on the immunogenicity response to vaccination was carried out using logistic regression analysis. Compared to the HC group, the positive response of IgG and Nab in RD patients were lower than those in healthy control (HC) ( P = .040 and P < .0001, respectively) after two doses of ICV were inoculated. The use of methotrexate ( P = .016) and prednisolone ( P = .018), and the level of red blood cell distribution width-C (RDW-C) ( P = .035) and C-reactive protein ( P = .015) were independently associated with lower rises in the magnitude of COVID-19 vaccine antibodies. No vaccine-related serious adverse reactions were observed in either group. After receiving two doses of ICVs, the production of protective antibodies in stable RD patients treated with immunosuppressive agents may decrease. It was discovered that ICVs were safe and well tolerated by RD patients.

Efficacy and safety of inactivated SARS‐CoV‐2 vaccination in COVID‐19‐associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real‐world retrospective observational study

“…Furthermore, they also found that the risk of COVID-19 infection in the Chinese population was low within 3 months following immunization, but that the protective effect of the vaccine would be weakened after 3 months. 4,14 Both the Korean College of Rheumatology and the American College of Rheumatology advise immunization for patients with RMDs. Regretfully, guidelines mostly concentrate on mRNA and adenovirus vaccines.…”

“…2 On the one hand, since immunosuppressive medications could lessen the immunogenicity of vaccines, patients might not have sufficient immune defenses. [3][4][5] On the other hand, patients worried that immunizations would disturb the delicate immunological homeostasis and worsen the underlying RMDs. 6,7 Currently, mRNA and adenovirus vaccines are the primary topics of study on COVID-19 vaccination of RMD patients.…”

Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis

“…Accordingly, the need for prophylactic vaccination with safety and efficacy is paramount to mitigate the severity of the disease ( 41 , 66 ). The commercially available vaccine included messenger RNA (mRNA) vaccine encoding the spike protein ( 67 ), adenovirus-based vaccine ( 68 ), and inactivated COVID-19 vaccination ( 69 ). Laboratory and clinical investigations were still accelerated to identify a new vaccine against SARS-CoV-2 virus variants ( 22 ).…”

“…Laboratory and clinical investigations were still accelerated to identify a new vaccine against SARS-CoV-2 virus variants ( 22 ). The effectiveness of two doses of mRNA vaccine against SARS-CoV-2 was 90–92% ( 70 ), while the effectiveness of the inactivated vaccine was more than 95% ( 69 ). As the vaccination effectively protected persons from being infected, long-term COVID-19 involving PCF was diminished ( 71 ).…”

Global Perspective on the Impact of the COVID‐19 Pandemic on Rheumatology and Health Equity

“…Despite the availability of vaccines, COVID‐19 vaccination rates in Asian countries, including China, remain low (27). Other than the messenger RNA and adenovirus vector vaccines used in western countries, inactivated COVID‐19 vaccines were widely used in China.…”